Up­dat­ed: No­var­tis ax­es PhI­II peanut al­ler­gy tri­al, ex­pects to test 'op­ti­mized dos­ing' in new tri­al lat­er this year

No­var­tis has again culled a late-stage tri­al of a bi­o­log­ic that it once thought could suc­ceed Xo­lair, its Genen­tech-part­nered an­ti-in­flam­ma­to­ry treat­ment for asth­ma and oth­er in­di­ca­tions.

The Swiss Big Phar­ma ter­mi­nat­ed a Phase III tri­al of lige­lizum­ab in pa­tients with peanut al­ler­gy, ac­cord­ing to a Jan. 16 up­date to the fed­er­al clin­i­cal tri­als data­base out­lin­ing the 52-week, ran­dom­ized study. The move comes af­ter an axe last Jan­u­ary in chron­ic in­ducible ur­ticaria (CIn­dU), an in­flam­ma­to­ry skin con­di­tion in which itchy welts and/or swelling goes on for more than six weeks.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER